Clinical characteristics of patients with MA-ILD (n = 54). Values are n (%) unless otherwise specified.
| Clinical Characteristics | Values |
|---|---|
| Age at onset, yrs, mean (SD) | 44.9 (14.9) |
| Sex | |
| Male | 16 (29.6) |
| Female | 38 (70.4) |
| Race | |
| Black | 26 (48.2) |
| White | 22 (40.7) |
| Hispanic | 4 (7.4) |
| Asian | 2 (3.7) |
| Smoking history | |
| Never | 38 (70.4) |
| Former | 12 (22.2) |
| Active | 4 (7.4) |
| Myositis | |
| Polymyositis | 30 (55.6) |
| Dermatomyositis | 20 (37.0) |
| CADM | 4 (7.4) |
| Baseline CK, U/l, mean (SD) | 2933.4 (4724.8) |
| Baseline aldolase, mean (SD) | 31.6 (32.2) |
| Serologic data | |
| ANA | 32 (59.3) |
| Anti-Jo1 | 27 (50.0) |
| SSA | 22 (40.7) |
| Mi-2 | 3 (5.6) |
| PL-7 | 1 (1.9) |
| SRP | 2 (3.7) |
| Ku | 1 (1.9) |
| PFT, %, mean (SD) | |
| FVC | 61.7 (19.6) |
| TLC | 68.6 (17.1) |
| DLCO | 57.9 (24.1) |
| CT chest | |
| Honeycombing absent | 38 (70.4) |
| Honeycombing present | 16 (29.6) |
| Lung histopathology | |
| OP | 5 (35.7) |
| NSIP | 3 (21.4) |
| UIP | 3 (21.4) |
| Others* | 3 (21.4) |
| Conventional DMARD | |
| AZA | 35 (64.8) |
| MTX | 17 (31.5) |
| MMF | 11 (20.4) |
↵* COP with NSIP, COP with hypersensitivity pneumonitis, and COP with diffuse alveolar damage. MA-ILD: myositis-associated interstitial lung disease; CADM: clinically amyopathic dermatomyositis; CK: creatine kinase; ANA: antinuclear antibody; SRP: signal recognition particle; PFT: pulmonary function test; FVC: forced vital capacity; TLC: total lung capacity; CT: computed tomography; OP: organizing pneumonia; COP: cryptogenic OP; NSIP: nonspecific interstitial pneumonia; UIP: usual inter-stitial pneumonia; DMARD: disease-modifying antirheumatic drugs; AZA: azathioprine; MTX: methotrexate; MMF: mycophenolate mofetil.